Stauning MA, Altintas I, Kallemose T, et al. - Researchers aimed at determining the utility of point-of-care measures of soluble urokinase plasminogen activator receptor (suPAR) in patients presenting at the emergency department (ED) with symptoms of COVID-19 for identification of patients that can be safely discharged. They conducted an observational cohort study of 386 patients who were admitted in the ED with symptoms of COVID-19. Of these patients, 171 (44%) patients had a mild disease trajectory, 79 (20%) a moderate, 63 (16%) a severe, and 73 (19%) a very severe disease trajectory. Findings suggest a potential utility of suPAR as a biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED. They identified a strong predictive value of low suPAR for mild disease trajectory. They identify a cut-off for discharge for suPAR< 2.0 ng/ml if suPAR is employed as a single parameter, and 3.0 ng/ml when combined with NEWS =< 4 and CRP < 10 mg/l^-. suPAR can be used even prior to identification of SARS-CoV-2 status.